To validate our findings, we carried out IHC staining of all the primary tumour samples using a customised in house immune panel to evaluate the presence of CD3+, CD8+, CD163+, FOXP3+ and PD-L1+ cells. The gene discussed is FOXP3; the disease is neoplasm.